In summary, we found that for elderly patients with advanced NSCLC, including those with high PS scores, brain metastases, or EGFR/ALK variations, combination therapy with low-dose nab-paclitaxel and tislelizumab is safe and has synergistic effects. This evidence concerns the gene EGFR and non-small cell lung carcinoma.